These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 35081742)

  • 1. Anthracycline-Induced Atrial Structural and Electrical Remodeling Characterizes Early Cardiotoxicity and Contributes to Atrial Conductive Instability and Dysfunction.
    Tan R; Cong T; Xu G; Hao Z; Liao J; Xie Y; Lin Y; Yang X; Li Q; Liu Y; Xia YL
    Antioxid Redox Signal; 2022 Jul; 37(1-3):19-39. PubMed ID: 35081742
    [No Abstract]   [Full Text] [Related]  

  • 2. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
    Wiseman LR; Spencer CM
    Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resveratrol significantly improves cell survival in comparison to dexrazoxane and carvedilol in a h9c2 model of doxorubicin induced cardiotoxicity.
    Monahan DS; Flaherty E; Hameed A; Duffy GP
    Biomed Pharmacother; 2021 Aug; 140():111702. PubMed ID: 34015579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling.
    Reichardt P; Tabone MD; Mora J; Morland B; Jones RL
    Future Oncol; 2018 Oct; 14(25):2663-2676. PubMed ID: 29747541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer.
    Ghasemi K; Vaseghi G; Mansourian M
    J Oncol Pharm Pract; 2021 Mar; 27(2):414-427. PubMed ID: 33081570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Lack of Synergy between Carvedilol and the Preventive Effect of Dexrazoxane in the Model of Chronic Anthracycline-Induced Cardiomyopathy.
    Szponar J; Ciechanski E; Ostrowska-Lesko M; Gorska A; Tchorz M; Dabrowska A; Dudka J; Murias M; Kowalczyk M; Korga-Plewko A; Mandziuk S
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.
    Schuler MK; Gerdes S; West A; Richter S; Busemann C; Hentschel L; Lenz F; Kopp HG; Ehninger G; Reichardt P; Pink D
    BMC Cancer; 2016 Aug; 16():619. PubMed ID: 27507014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dexrazoxane: a cardioprotectant for pediatric cancer patients receiving anthracyclines.
    Wu V
    J Pediatr Oncol Nurs; 2015; 32(3):178-84. PubMed ID: 25366577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.
    Stěrba M; Popelová O; Vávrová A; Jirkovský E; Kovaříková P; Geršl V; Simůnek T
    Antioxid Redox Signal; 2013 Mar; 18(8):899-929. PubMed ID: 22794198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
    Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
    J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation.
    Jirkovský E; Jirkovská A; Bavlovič-Piskáčková H; Skalická V; Pokorná Z; Karabanovich G; Kollárová-Brázdová P; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Lyon AR; Roh J; Šimůnek T; Štěrbová-Kovaříková P; Štěrba M
    Circ Heart Fail; 2021 Nov; 14(11):e008209. PubMed ID: 34551586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention.
    Bhagat A; Kleinerman ES
    Adv Exp Med Biol; 2020; 1257():181-192. PubMed ID: 32483740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of cardiotoxicity of anthracycline-containing chemotherapy regimens in patients with bone and soft tissue sarcomas: A study of the FDA adverse event reporting system joint single-center real-world experience.
    Mo Z; Deng Y; Bao Y; Liu J; Jiang Y
    Cancer Med; 2023 Dec; 12(24):21709-21724. PubMed ID: 38054208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
    Henriksen PA
    Heart; 2018 Jun; 104(12):971-977. PubMed ID: 29217634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled trial (CarDHA trial).
    Carrasco R; Ramirez MC; Nes K; Schuster A; Aguayo R; Morales M; Ramos C; Hasson D; Sotomayor CG; Henriquez P; Cortés I; Erazo M; Salas C; Gormaz JG
    Trials; 2020 Feb; 21(1):137. PubMed ID: 32019575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron.
    Simůnek T; Stérba M; Popelová O; Adamcová M; Hrdina R; Gersl V
    Pharmacol Rep; 2009; 61(1):154-71. PubMed ID: 19307704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased Soluble Guanylate Cyclase Contributes to Cardiac Dysfunction Induced by Chronic Doxorubicin Treatment in Mice.
    Vandenwijngaert S; Swinnen M; Walravens AS; Beerens M; Gillijns H; Caluwé E; Tainsh RE; Nathan DI; Allen K; Brouckaert P; Bartunek J; Scherrer-Crosbie M; Bloch KD; Bloch DB; Janssens SP; Buys ES
    Antioxid Redox Signal; 2017 Feb; 26(4):153-164. PubMed ID: 27505125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
    Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
    Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience.
    Testore F; Milanese S; Ceste M; de Conciliis E; Parello G; Lanfranco C; Manfredi R; Ferrero G; Simoni C; Miglietta L; Ferro S; Giaretto L; Bosso G
    Am J Cardiovasc Drugs; 2008; 8(4):257-63. PubMed ID: 18690759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.